Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Spanish Cooperative Group for Digestive Tumour Therapy (TTD) Identifier:
First received: August 12, 2008
Last updated: February 19, 2013
Last verified: February 2013

The purpose of the study is to determine efficacy ans safety of the combination of cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil) as neoadjuvant therapy followed concomitant chemoradiotherapy (cisplatin) plus cetuximab in patients with a locoregional esophageal carcinoma

Condition Intervention Phase
Esophageal Carcinoma
Drug: cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II, Multicentre, Uncontrolled Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Chemotherapy (Docetaxel, Cisplatin, 5-fluorouracil) as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy (Cisplatin) Plus Cetuximab in Patients With a Locoregional Esophageal Carcinoma

Resource links provided by NLM:

Further study details as provided by Spanish Cooperative Group for Digestive Tumour Therapy (TTD):

Primary Outcome Measures:
  • • Complete clinical response rate and objective clinical response rate after the administration of 3 cycles of chemotherapy plus cetuximab and after induction chemotherapy followed by concomitant chemoradiotherapy plus cetuximab [ Time Frame: 2006-2010 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • • To determine the complete pathological response rate in the patients subject to radical surgery, according to the investigators' criteria and the policy of each centre. [ Time Frame: 2006-2010 ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 2006-2010 ] [ Designated as safety issue: Yes ]
  • • To study the locoregional control of the disease, the therapeutic failure patterns, specific disease-free survival, event-free survival, disease-specific survival and global survival [ Time Frame: 2006-2012 ] [ Designated as safety issue: No ]
  • • To determine EGFR expression in the tumour and attempt to correlate it with efficacy [ Time Frame: 2006-2010 ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: December 2006
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)

Neoadjuvant chemotherapy plus cetuximab:

3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.

Radio-chemotherapy plus cetuximab:

The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).

Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent form signed before performing any of the study's specific procedures.
  • Age > 18 and < 70.
  • Karnofsky performance status > 70% upon inclusion in the study.
  • Life expectancy of more than 3 months.
  • Histologically confirmed diagnosis of squamous cell carcinoma or adenocarcinoma of the oesophagus or the gastroesophageal junction. The disease must be confined to the oesophagus or gastroesophageal junction and the perioesophageal region. There must be no tumor extension beyond 2 cm into the stomach.
  • Stages II or III. The patients must have a T1N1M0 or T2-4; any N; M0. The only exception would be patients with stage IVA: an oesophageal carcinoma of the upper thoracic region with metastasis in cervical lymph nodes (M1a) and an oesophageal carcinoma of the lower thoracic region with metastasis in the celiac lymph nodes (M1a), providing the disease remains within the radiotherapy fields.
  • Presence of a unidimensionally measurable and/or assessable lesion
  • Neutrophils >1500/mm3, platelet count >150,000/mm3 and haemoglobin >10 g/dl.
  • Adequate renal function: serum creatinine < 120 micromol/l (1.4 mg/dl); if the values are >120 micromol/l (1.4 mg/dl) creatinine clearance must be > 65 ml/min.
  • Adequate liver function: total bilirubin <1 x NUL; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 x NUL; alkaline phosphatase (AP) < 5 x NUL. Patients with AST and/or ALT > 1.5 < 2.5 x NUL and AP > 1.5 x NUL < 5 x NUL are not eligible.
  • Serum calcium <1.25 x normal upper limit (NUL).
  • Adequate nutritional status: weight loss < 20% of regular weight and albumin > 35 g/l.
  • Total oral and/or enteral intake should be at least 1700 calories/day.
  • Use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy.
  • Availability of tumour tissue for immunohistochemical analysis of EGFR expression and other biological markers.

Exclusion Criteria:

  • Patients with a tracheo-oesophageal fistula or direct invasion of the tracheal mucosa or a major bronchi are not eligible. Bronchoscopy (with biopsy and cytology if lesion is seen) is required in order to rule out a fistula and/or direct invasion if the primary tumour is < than 30 cm from the incisors. Bronchoscopy is also required when the primary tumour is shown to be at or above the carina by an imaging study.
  • Prior thoracic radiotherapy and/or systemic chemotherapy and/or oesophageal surgery.
  • Patients with multiple carcinoma of the oesophagus.
  • Diagnosis of any other cancer in the previous 5 years with the exception of appropriately treated carcinoma in situ of the uterine cervix and/or basal cell carcinoma of the skin.
  • Systemic, chronic and concomitant immune treatment, or anti-cancer hormone therapy.
  • Other concomitant cancer treatments.
  • Active infection (infection requiring intravenous antibiotics), including active tuberculosis and diagnosed HIV.
  • Uncontrolled hypertension defined as systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 130 mmHg at rest.
  • Active, uncontrolled, gastric or duodenal peptic ulcer.
  • Chronic obstructive pulmonary disease requiring hospitalisation in the 6 months prior to inclusion in the study.
  • History of atrioventricular arrhythmia and/or cardiac failure and/or second or third degree heart block.
  • Clinically significant coronary artery disease or history of myocardial infarction in the last 12 months .
  • Peripheral neuropathy grade > 2 NCIC-CTG of any aetiology.
  • Hearing disorder grade > 2 NCIC-CTG of any aetiology.
  • Any other disease or medical disorder suggesting that the patient will not be able to complete the study.
  • Any psychological disorder suggesting that the complete treatment will not be possible.
  • Pregnancy (its absence must be confirmed by the serum HCG-betatest) or lactation.
  • Known drug abuse (with the exception of the mild or moderate consumption of alcohol upon inclusion in the study).
  • Known allergic reaction to any of the components in the study treatment.
  • Prior treatment with monoclonal antibodies or other signal transduction inhibitors or EGFR-targeted treatment.
  • Evidence of another cancer, with the exception of a carcinoma in situ of the uterine cervix and/or a basal cell carcinoma of the skin.
  • Any experimental treatment in the 30 days prior to inclusion in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00733889

Spanish Cooperative Group for Gastrointestinal Tumour Therapy
Madrid, Spain, 28046
Sponsors and Collaborators
Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Merck Sharp & Dohme Corp.
Study Chair: Josep Tabernero, MD; phD Medical Oncology Department; Hospital Universitario Vall d'Hebrón; Barcelona
Study Chair: Jordi Giralt, MD; phD Oncology Radiation Department; Hospital Universitario Vall d'Hebrón; Barcelona
  More Information

No publications provided

Responsible Party: Spanish Cooperative Group for Digestive Tumour Therapy (TTD) Identifier: NCT00733889     History of Changes
Other Study ID Numbers: TTD-06-02, EudraCT number:2006-001880-42
Study First Received: August 12, 2008
Last Updated: February 19, 2013
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Spanish Cooperative Group for Digestive Tumour Therapy (TTD):
esophageal carcinoma

Additional relevant MeSH terms:
Esophageal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Esophageal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators processed this record on March 03, 2015